Nanobiotix starts a new research program, in Immuno Oncology, with its lead product NBTXR3
January 05 2016 - 2:31AM
NANOBIOTIX (Euronext: NANO - ISIN:
FR0011341205), a late clinical-stage
nanomedicine company pioneering novel approaches for the local
treatment of cancer, announces today that, in addition to its
current advanced clinical development program, the Company has
started exploring the use of NBTXR3 for combination in Immuno
Oncology.
Elsa Borghi, Nanobiotix's Medical Director, commented: "With six
ongoing indications, our global clinical development of NBTXR3 as a
radio-enhancer, is progressing well. This Immuno Oncology program
could bring new applications and confirm that additional patient
populations could benefit from treatment with NBTXR3".
NBTXR3 current clinical development
NBTXR3 is a radio-enhancer, using a physical mode of action to
destroy cancer cells in any solid tumors, in combination with
radiotherapy.
Nanobiotix is running a global clinical development program with
its lead product NBTXR3, in six indications across Europe, the US
and the Asia-Pacific Region: a registration trial in soft tissue
sarcoma, and Phase I/II trials in liver cancers (HCC and liver
metastases), prostate cancer, head and neck cancer and rectal
cancer (in Asia by Nanobiotix's partner PharmaEngine).
In situ (intratumoral) vaccination with NBTXR3 opens new
potential prospects in Immuno Oncology
The aim of Immuno Oncology (IO) is to boost patients' immune
systems to fight cancer, through different approaches. It is very
efficient for a limited number of patients whose tumors have
natural and sufficient immunogenicity. However, to exploit the full
potential of immune therapies it is necessary to increase this
immunogenicity at tumor level.
Indeed, it has been demonstrated that radiotherapy can be used
to improve immunogenicity, by creating Immunogenic Cell Death (ICD)
in many situations.
NBTXR3 nanoparticles' activation enhances the energy deposited
where they are injected, improving the cancer cell death and
efficacy of radiotherapy. This technology is based on physics and
can potentially be applied across all radiotherapy indications. All
preclinical model have shown a systematic superiority of cell
killing, when using NBTXR3 with radiotherapy, compared to
radiotherapy alone.
Hence, NBTXR3 could have the potential to be used as an in situ
(intratumoral) vaccination that would create ICDs which, in turn,
could bring a new dimension and broaden the usage of immuno
therapies in oncology.
To explore this brand new field of development opportunities,
the Company has launched a pre-clinical development program.
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late
clinical-stage nanomedicine company pioneering novel approaches for
the local treatment of cancer. The Company's first-in-class,
proprietary technology, NanoXray, enhances radiotherapy energy with
a view to provide a new, more efficient treatment for cancer
patients.
NanoXray products are compatible with current radiotherapy
treatments and are meant to treat potentially a wide variety of
solid tumors s including soft tissue sarcoma, head and neck
cancers, liver cancers, prostate cancer, breast cancer,
glioblastoma, etc., via multiple routes of administration.
Nanobiotix's lead product NBTXR3, based on NanoXray, is
currently under clinical development for soft tissue sarcoma, head
and neck Cancer, prostate cancer, rectal cancer (PharmaEngine) and
liver cancers (HCC and liver metastases). The Company has partnered
with PharmaEngine for clinical development and commercialization of
NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in
Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO:
FP). The Company Headquarter is based in Paris, France. Affiliate
in Cambridge, United States.
Contact
Nanobiotix |
|
Sarah Gaubert Head of Communication and Public Affairs +33 (0)1 40
26 07 55 contact@nanobiotix.com |
|
Media relations |
France - NewCap
Annie-Florence Loyer +33 (0)6 88 20 35 59 afloyer@newcap.fr |
|
Outside France -
Instinctif Partners Melanie Toyne Sewell +44 (0) 207 457 2020
nanobiotix@instinctif.com |
Disclaimer
This press release contains certain forward-looking statements
concerning Nanobiotix and its business. Such forward-looking
statements are based on assumptions that Nanobiotix considers to be
reasonable. However, there can be no assurance that the estimates
contained in such forward-looking statements will be verified,
which estimates are subject to numerous risks including the risks
set forth in the 2014 annual financial report of Nanobiotix (a copy
of which is available on www.nanobiotix.com) and to the development
of economic conditions, financial markets and the markets in which
Nanobiotix operates. The forward-looking statements contained in
this press release are also subject to risks not yet known to
Nanobiotix or not currently considered material by Nanobiotix. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Nanobiotix to
be materially different from such forward-looking statements.
This press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Nanobiotix shares in any
country.
HUG#1976503
Nanobiotix (EU:NANO)
Historical Stock Chart
From May 2024 to Jun 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Jun 2023 to Jun 2024